MedTrace Logo

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

NCT06714591 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-12-31

No results posted yet for this study

Summary

The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.

Conditions

  • Relapsed/Refractory Acute Myeloid Leukemia

Interventions

DRUG

BL-M11D1

The study includes 2 parts: Part 1 Dose escalation and Dose Finding

Sponsors & Collaborators

  • SystImmune Inc.

    lead INDUSTRY

Principal Investigators

  • Loren VanPelt · SystImmune Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-19
Primary Completion
2026-12-31
Completion
2027-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06714591 on ClinicalTrials.gov